Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention

• Published in: Nature communications Vol. 8; no. 1; p. 14683
• Main Authors: Bohnacker, Thomas, Prota, Andrea E., Beaufils, Florent, Burke, John E., Melone, Anna, Inglis, Alison J., Rageot, Denise, Sele, Alexander M., Cmiljanovic, Vladimir, Cmiljanovic, Natasa, Bargsten, Katja, Aher, Amol, Akhmanova, Anna, Díaz, J. Fernando, Fabbro, Doriano, Zvelebil, Marketa, Williams, Roger L., Steinmetz, Michel O., Wymann, Matthias P.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 09.03.2017; Nature Publishing Group; Nature Portfolio
• Subjects: 13/95; 14/1; 14/19; 14/63; 631/45/535/1266; 631/67/1059/153; 631/80/128/1653; 631/80/86/2364; 82/47; Aminopyridines - chemistry; Aminopyridines - pharmacology; Biochemistry; Biology; Cancer; Cell cycle; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Crystallography, X-Ray; HCT116 Cells; Humanities and Social Sciences; Humans; Kinases; Medical research; Molecular Structure; Morpholines - chemistry; Morpholines - pharmacology; multidisciplinary; Phosphatidylinositol 3-Kinases - chemistry; Phosphatidylinositol 3-Kinases - metabolism; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Science; Tubulin - chemistry; Tubulin - metabolism; Tubulin Modulators - chemistry; Tubulin Modulators - pharmacology; United Kingdom > UK; Basel Switzerland; Switzerland
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/ncomms14683

BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization. Here, we developed two chemical derivatives that differ from BKM120 by only one atom. We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors. Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K. Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs. Our results raise concerns over BKM120’s generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies. Buparlisib/BKM120 is in phase 3 clinical trials as a phosphoinositide 3-kinase (PI3K) inhibitor. Here, Bohnacker et al . combine chemical biology and structural biology approaches to segregate BKM120’s biological actions, and suggest that it causes mitotic arrest predominantly by binding microtubules and disrupting their dynamics.